SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Sep 28, 2010

AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Sept. 28, 2010 · CIK: 0000946644 · Accession: 0001144204-10-051231

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

December 31, 2009

Author

Bernhardt

Form

CORRESP

Company

AIM ImmunoTech Inc. (AIM) (CIK 0000946644)

Letter

Division of Corporation Finance Securities and Exchange Commission Hemispherx Biopharma, Inc. Form 10-K for the year ended December 31, 2009 Form 10-K/A for the year ended December 31, 2009 (SEC filing No. 1-13441)

Dear Mr. Rosenberg:

We hereby confirm receipt of your September 15, 2010 comment letter related to the above referenced Form 10-K and Form 10-K/A of Hemispherx Biopharma, Inc.

We anticipate that we will be filing our response to the comment letter on EDGAR on or before October 14, 2010.

If you have any questions, please do not hesitate to contact me at (215) 988-0080.

Very
truly yours,
/s/ Charles T.
Bernhardt

Show Raw Text

CORRESP
1
filename1.htm

    Unassociated Document

    September
28, 2010

    Jim B.
Rosenberg

    Senior
Assistant Chief Accountant

    Division
of Corporation Finance

    Securities
and Exchange Commission

    100 F
Street, NE

    Washington,
DC 20549

                Re:

                Hemispherx
      Biopharma, Inc.

                Form
      10-K for the year ended December 31, 2009

                Form
      10-K/A for the year ended December 31, 2009

                (SEC filing No.
  1-13441)

    Dear Mr.
Rosenberg:

    We hereby
confirm receipt of your September 15, 2010 comment letter related to the above
referenced Form 10-K and Form 10-K/A of Hemispherx Biopharma, Inc.

    We
anticipate that we will be filing our response to the comment letter on EDGAR on
or before October 14, 2010.

    If you
have any questions, please do not hesitate to contact me at (215)
988-0080.

    Very
truly yours,

    /s/ Charles T.
Bernhardt

    Charles T. Bernhardt,

    Chief
Financial Officer

    Corporate
Headquarters

              One Penn Center, 1617 JFK
      Blvd., Philadelphia, PA  19103

            t:
      215-988-0080
            f:
      215-988-1739

SecProbe.io